Dr. Massimo Cristofanilli Discusses ALK Amplification in Inflammatory Breast Cancer
3 vistas
• 07/03/23
0
0
Empotrar
administrator
Suscriptores
Massimo Cristofanilli, MD, Chair in Medical Oncology, Director of Translational Science, Cancer Genome Institute, Fox Chase Cancer Center, discusses the investigation of small-molecule anaplastic lymphoma kinase (ALK) inhibitors to treat patients with inflammatory breast cancer (IBC).
For more information on targeted therapies, visit http://www.onclive.com/specialty/cancer-pathways
Mostrar más
Comentarios de Facebook
SORT BY-
Top Comentarios
-
Últimos comentarios